Does a breast cancer patient need a genetic test?

Does a breast cancer patient need a genetic test? Does a breast cancer patient need a genetic test?Based on data published by WHO. In 2020, for the first time, the number of cases of breast cancer worldwide surpassed lung cancer, making it the world ‘ s largest. In 2020, the number of new cases of breast cancer among women was 420,000, the highest number of cancer cases among women. During the day-to-day treatment of many breast cancer patients, they are often told of the need for genetic testing, so is there any need for genetic testing for breast cancer patients?In order to answer this question to a large number of patients, we first need to understand that breast cancer is stymied according to the type of gene receptor and the type of pathology, with different types of risk of re-emerging breast cancer. Common genetic tests for breast cancer include the BRCA1/2 and breast cancer 21 and breast cancer 70.1. BRCA1/2 Genetic TestingThe BRCA1/2 gene is the genetic source of breast cancer, and the BRCA1/2 gene itself is a canceric gene, whose mutation is a major predictor of breast cancer. A considerable amount of literature suggests that about 5 to 6 per cent of breast cancer patients may have been caused by a genetic mutation of the BRCA1/2 gene, with about 75 per cent of women carrying the BRCA1/2 mutation gene at risk of contracting breast cancer before the age of 80. Therefore, we suggest that all women with the BRCA1/2 mutation genes may choose preventive surgery, such as a simple mammography, ovarian ovary hysterectomy, etc., such as Angelina Julie, the American actress.As a result, BRCA1/2 genetic tests are necessary for three-negative breast cancers at higher risk of recurrence and for the health of close relatives with breast cancer.2. Breast cancer 21 Genetic TestingGenetic breast cancer 21 is one of the most common clinical indicators for predicting breast cancer, which not only predicts the long-term risk of re-emergence of early breast cancer, a type of estrogen-positive breast cancer, but also assesses the need for and benefits from chemotherapy for breast cancer patients, and provides useful information on the prognosis, re-emergence and counselling of breast cancer to help with individualized treatment.Thus, we often recommend 21-genetic tests when we decide whether hormonal positive early breast cancer patients need chemotherapy. Based on the 21-genetic (RS) values, 1. If RS Z15 is required only for endocrine treatment, chemotherapy does not benefit at all; 2. If RS is 16-25, chemotherapy + endocrine treatment is recommended, or ovarian inhibition + endocrine medicine (with minor benefit added to the chemotherapy group, but it is unclear whether this benefit is due to ovarian inhibition due to chemotherapy); 3.RS Z26 points suggest a higher risk of re-emergence of chemotherapy + endocrine treatment.3. Breast cancer 70 genetic tests The purpose of genetic testing is to test whether high-risk patients in clinical settings, such as those with lymphorate transfer, can be exempted from chemotherapy at genetic level. Genetic testing itself has a scoring rule: 1. For patients with low scoring, even though there is lymphoma transfer, large data support only endocrinological treatment can provide better treatment, and chemotherapy does not benefit. 2. For patients with a high score, large data show that this group of patients is not enough for endocrine treatment alone, and chemotherapy is needed to further reduce the risk of relapse. This group of patients requires chemotherapy, which is followed by endocrine treatment. So 70 genetic tests are applied to re-emergence risks of lymphoma transfer, but for those who themselves resist chemotherapy, 70 genetic tests can be performed first to determine if chemotherapy benefits. In the light of the above, genetic tests for specific breast cancer patients or health groups can reveal a mutation of the genes and indicate the risk of re-emergence and even the benefits of chemotherapy.